Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

Most download

Page Path
HOME > Browse Articles > Most download
156 Most download
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles

Most-download articles are from the articles published in 2023 during the last three month.

Review Articles
Article image
Functional Movement Disorders: Updates and Clinical Overview
Jung E Park
J Mov Disord. 2024;17(3):251-261.   Published online July 1, 2024
DOI: https://doi.org/10.14802/jmd.24126
  • 10,223 View
  • 603 Download
  • 2 Crossref
AbstractAbstract PDF
Functional movement disorder (FMD) is a type of functional neurological disorder that is common but often difficult to diagnose or manage. FMD can present as various phenotypes, including tremor, dystonia, myoclonus, gait disorders, and parkinsonism. Conducting a clinical examination appropriate for assessing a patient with suspected FMD is important, and various diagnostic testing maneuvers may also be helpful. Treatment involving a multidisciplinary team, either outpatient or inpatient, has been found to be most effective. Examples of such treatment protocols are also discussed in this review. While recognition and understanding of the disorder has improved over the past few decades, as well as the development of treatments, it is not uncommon for patients and physicians to continue to experience various difficulties when dealing with this disorder. In this review, I provide a practical overview of FMD and discuss how the clinical encounter itself can play a role in patients’ acceptance of the diagnosis. Recent neuroimaging studies that aid in understanding the pathophysiology are also discussed.

Citations

Citations to this article as recorded by  
  • Reduced microstructural white matter integrity is associated with the severity of physical symptoms in functional neurological disorder
    Nicolas Gninenko, Eliane Müller, Selma Aybek
    NeuroImage: Clinical.2025; : 103791.     CrossRef
  • Clinical insights into movement disorders in children: A review of etiology, diagnosis, and treatment options
    Aron Christy, Ramya A
    IP International Journal of Medical Paediatrics and Oncology.2024; 10(4): 103.     CrossRef
Article image
Non-Motor Fluctuations in Parkinson’s Disease: Underdiagnosed Yet Important
Iro Boura, Karolina Poplawska-Domaszewicz, Cleanthe Spanaki, Rosabel Chen, Daniele Urso, Riaan van Coller, Alexander Storch, Kallol Ray Chaudhuri
J Mov Disord. 2025;18(1):1-16.   Published online December 20, 2024
DOI: https://doi.org/10.14802/jmd.24227
  • 2,204 View
  • 240 Download
  • 1 Web of Science
  • 2 Crossref
AbstractAbstract PDF
Non-motor fluctuations (NMFs) in Parkinson’s disease (PD) significantly affect patients’ well-being. Despite being identified over two decades ago, NMFs remain largely underrecognized, undertreated, and poorly understood. While they are often temporally associated with motor fluctuations (MFs) and can share common risk factors and pathophysiologic mechanisms, NMFs and MFs are currently considered distinct entities. The prevalence and severity of NMFs, often categorized into neuropsychiatric, sensory, and autonomic subtypes, vary significantly across studies due to the heterogeneous PD populations screened and the diverse evaluation tools applied. The consistent negative impact of NMFs on PD patients’ quality of life underscores the importance of further investigations via focused and controlled studies, validated assessment instruments and novel digital technologies. High-quality research is essential to illuminate the complex pathophysiology and clinical nuances of NMFs, ultimately enhancing clinicians’ diagnostic and treatment options in routine clinical practice.

Citations

Citations to this article as recorded by  
  • Managing non-motor symptoms of Parkinson disease in China: clinical perspectives
    Jing Chen, Xiaotong Feng, Danhua Zhao, Baoyu Chen, Chaobo Bai, Qi Wang, Yuan Li, Junyi Chen, Xintong Guo, Jinjin Wang, Lin Zhang, Junliang Yuan
    BMC Neurology.2025;[Epub]     CrossRef
  • Post hoc exploratory analysis of the effect of foslevodopa/foscarbidopa continuous subcutaneous infusion on nocturia in patients with Parkinson’s disease
    K. Ray Chaudhuri, Manon Bouchard, Eric Freire-Alvarez, Rajesh Pahwa, Lars Bergmann, Resmi Gupta, Pavnit Kukreja, Megha B. Shah, Stuart H. Isaacson
    Clinical Parkinsonism & Related Disorders.2025; : 100330.     CrossRef
Article image
Drug Repositioning and Repurposing for Disease-Modifying Effects in Parkinson’s Disease
Seong Ho Jeong, Phil Hyu Lee
J Mov Disord. 2025;18(2):113-126.   Published online February 7, 2025
DOI: https://doi.org/10.14802/jmd.25008
  • 1,228 View
  • 161 Download
AbstractAbstract PDF
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder and is characterized by progressive dopaminergic and nondopaminergic neuronal loss and the presence of Lewy bodies, which are primarily composed of aggregated α-synuclein. Despite advancements in symptomatic therapies, such as dopamine replacement and deep brain stimulation, no disease-modifying therapies (DMTs) have been identified to slow or arrest neurodegeneration in patients with PD. Challenges in DMT development include disease heterogeneity, the absence of reliable biomarkers, and the multifaceted pathophysiology of PD, encompassing neuroinflammation, mitochondrial dysfunction, lysosomal impairment, and oxidative stress. Drug repositioning and repurposing strategies using existing drugs for new therapeutic applications offer promising approaches to accelerate the development of DMTs for PD. These strategies minimize time, cost, and risk by using compounds with established safety profiles. Prominent candidates include glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, ambroxol, calcium channel blockers, statins, iron-chelating agents, c-Abl inhibitors, and memantine. Although preclinical and early clinical studies have demonstrated encouraging results, numerous phase III trials have yielded unfavorable outcomes, elucidating the complexity of PD pathophysiology and the need for innovative trial designs. This review evaluates the potential of prioritized repurposed drugs for PD, focusing on their mechanisms, preclinical evidence, and clinical trial outcomes, and highlights the ongoing challenges and opportunities in this field.
Original Article
Article image
Gait Instability and Compensatory Mechanisms in Parkinson’s Disease Patients With Camptocormia: An Exploratory Study
Hideyuki Urakami, Yasutaka Nikaido, Yuta Okuda, Yutaka Kikuchi, Ryuichi Saura, Yohei Okada
J Mov Disord. 2025;18(2):127-137.   Published online December 27, 2024
DOI: https://doi.org/10.14802/jmd.24226
  • 1,368 View
  • 194 Download
AbstractAbstract PDFSupplementary Material
Objective
Camptocormia contributes to vertical gait instability and, at times, may also lead to forward instability in experimental settings in Parkinson’s disease (PD) patients. However, these aspects, along with compensatory mechanisms, remain largely unexplored. This study comprehensively investigated gait instability and compensatory strategies in PD patients with camptocormia (PD+CC).
Methods
Ten PD+CC patients, 30 without camptocormia (PD-CC), and 27 healthy controls (HCs) participated. Self-paced gait tasks were analyzed using three-dimensional motion capture systems to assess gait stability as well as spatiotemporal and kinematic parameters. Unique cases with pronounced forward gait stability or instability were first identified, followed by group comparisons. Correlation analysis was performed to examine associations between trunk flexion angles (lower/upper) and gait parameters. The significance level was set at 0.05.
Results
Excluding one unique case, the PD+CC group presented a significantly lower vertical center of mass (COM) position (p=0.019) increased mediolateral COM velocity (p=0.004) and step width (p=0.013), compared to the PD-CC group. Both PD groups presented greater anterior‒posterior margins of stability than did the HCs (p<0.001). Significant correlations were found between lower/upper trunk flexion angles and a lower vertical COM position (r=-0.690/-0.332), as well as increased mediolateral COM velocity (r=0.374/0.446) and step width (r=0.580/0.474).
Conclusion
Most PD+CC patients presented vertical gait instability, increased fall risk, and adopted compensatory strategies involving greater lateral COM shift and a wider base of support, with these trends intensifying as trunk flexion angles increased. These findings may guide targeted interventions for gait instability in PD+CC patients.
Letter to the editor
Article image
Levodopa Pharmacokinetics in Switching From Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson’s Disease: A Case Report
Tomonori Nukariya, Toshiki Tezuka, Shohei Okusa, Ryotaro Okochi, Yuto Sakai, Yoshihiro Nihei, Jin Nakahara, Morinobu Seki
J Mov Disord. 2025;18(2):179-181.   Published online January 6, 2025
DOI: https://doi.org/10.14802/jmd.24247
  • 1,163 View
  • 224 Download
  • 1 Web of Science
  • 1 Crossref
PDF

Citations

Citations to this article as recorded by  
  • Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease
    Sacha Brohée, Emmanuel Roze, David Grabli, Hélène Letrillart, Lise Mantisi, Cendrine Foucard, Elodie Hainque, Florence Cormier, Aurélie Méneret, Fabien Hauw
    Movement Disorders Clinical Practice.2025;[Epub]     CrossRef
Review Articles
Article image
α-Synuclein: A Promising Biomarker for Parkinson’s Disease and Related Disorders
Taku Hatano, Ayami Okuzumi, Gen Matsumoto, Taiji Tsunemi, Nobutaka Hattori
J Mov Disord. 2024;17(2):127-137.   Published online April 9, 2024
DOI: https://doi.org/10.14802/jmd.24075
  • 6,895 View
  • 498 Download
  • 5 Web of Science
  • 6 Crossref
AbstractAbstract PDF
Mutations in the SNCA gene, which encodes α-synuclein (α-syn), play a key role in the development of genetic Parkinson’s disease (PD). α-Syn is a major component of Lewy bodies in PD and glial cytoplasmic inclusions in multiple system atrophy (MSA). Rapid eye movement sleep behavior disorder patients often progress to PD, dementia with Lewy bodies, or MSA, which are collectively known as α-synucleinopathies. The loss of dopaminergic neurons with Lewy bodies precedes motor dysfunction in these diseases, but the mechanisms of neurodegeneration due to α-syn aggregation are poorly understood. Monitoring α-syn aggregation in vivo could serve as a diagnostic biomarker and help elucidate pathogenesis, necessitating a simple and accurate detection method. Seed amplification assays (SAAs), such as real-time quaking-induced conversion and protein misfolding cyclic amplification, are used to detect small amounts of abnormally structured α-syn protofibrils, which are central to aggregation. These methods are promising for the early diagnosis of α-synucleinopathy. Differences in α-syn filament structures between α-synucleinopathies, as observed through transmission electron microscopy and cryo-electron microscopy, suggest their role in the pathogenesis of neurodegeneration. SAAs may differentiate between subtypes of α-synucleinopathy and other diseases. Efforts are also being made to identify α-syn from blood using various methods. This review introduces body fluid α-syn biomarkers based on pathogenic α-syn seeds, which are expected to redefine α-synucleinopathy diagnosis and staging, improving clinical research accuracy and facilitating biomarker development.

Citations

Citations to this article as recorded by  
  • Selective detection of alpha synuclein amyloid fibrils by faradaic and non-faradaic electrochemical impedance spectroscopic approaches
    Hussaini Adam, Subash C.B. Gopinath, Hemavathi Krishnan, Tijjani Adam, Makram A. Fakhri, Evan T. Salim, A. Shamsher, Sreeramanan Subramaniam, Yeng Chen
    Bioelectrochemistry.2025; 161: 108800.     CrossRef
  • Evolving Landscape of Parkinson’s Disease Research: Challenges and Perspectives
    Rumiana Tenchov, Janet M. Sasso, Qiongqiong Angela Zhou
    ACS Omega.2025; 10(2): 1864.     CrossRef
  • Seeding amplification assay: Limitations and insights for enhanced clinical and research applications
    Ilham Y Abdi, Sara A Hashish, Omar A El-Agnaf
    Journal of Parkinson’s Disease.2025;[Epub]     CrossRef
  • Elucidating Pathological Mechanisms and Developing Biomarkers of Parkinson's Disease
    Taku Hatano
    Neurology and Clinical Neuroscience.2025;[Epub]     CrossRef
  • Hypoxia Pathways in Parkinson’s Disease: From Pathogenesis to Therapeutic Targets
    Yuanyuan Gao, Jiarui Zhang, Tuoxian Tang, Zhenjiang Liu
    International Journal of Molecular Sciences.2024; 25(19): 10484.     CrossRef
  • Circadian rhythm disruption: a potential trigger in Parkinson’s disease pathogenesis
    Ke Xu, Yu Zhang, Yue Shi, Yake Zhang, Chengguang Zhang, Tianjiao Wang, Peizhu Lv, Yan Bai, Shun Wang
    Frontiers in Cellular Neuroscience.2024;[Epub]     CrossRef
Article image
Gastrointestinal Dysfunction in Parkinson’s Disease: Neuro-Gastroenterology Perspectives on a Multifaceted Problem
Ai Huey Tan, Kee Huat Chuah, Yuan Ye Beh, Jie Ping Schee, Sanjiv Mahadeva, Shen-Yang Lim
J Mov Disord. 2023;16(2):138-151.   Published online May 24, 2023
DOI: https://doi.org/10.14802/jmd.22220
  • 12,208 View
  • 378 Download
  • 13 Web of Science
  • 15 Crossref
AbstractAbstract PDF
Patients with Parkinson’s disease (PD) face a multitude of gastrointestinal (GI) symptoms, including nausea, bloating, reduced bowel movements, and difficulties with defecation. These symptoms are common and may accumulate during the course of PD but are often under-recognized and challenging to manage. Objective testing can be burdensome to patients and does not correlate well with symptoms. Effective treatment options are limited. Evidence is often based on studies in the general population, and specific evidence in PD is scarce. Upper GI dysfunction may also interfere with the pharmacological treatment of PD motor symptoms, which poses significant management challenges. Several new less invasive assessment tools and novel treatment options have emerged in recent years. The current review provides an overview and a practical approach to recognizing and diagnosing common upper and lower GI problems in PD, e.g., dyspepsia, gastroparesis, small bowel dysfunction, chronic constipation, and defecatory dysfunction. Management aspects are discussed based on the latest evidence from the PD and general populations, with insights for future research pertaining to GI dysfunction in PD.

Citations

Citations to this article as recorded by  
  • Lactiplantibacillus plantarum SG5 inhibits neuroinflammation in MPTP-induced PD mice through GLP-1/PGC-1α pathway
    Yueyan Qi, Yuxuan Dong, Jinhu Chen, Siyou Xie, Xin Ma, Xueping Yu, Yang Yu, Yanqin Wang
    Experimental Neurology.2025; 383: 115001.     CrossRef
  • Gastrointestinal Dysfunction Bears on the Clinical‐Biological Profile of Parkinson's Disease
    Jacopo Bissacco, Roberta Bovenzi, Matteo Conti, Clara Simonetta, Davide Mascioli, Rocco Cerroni, Giulia Maria Sancesario, Piergiorgio Grillo, Mariangela Pierantozzi, Alessandro Stefani, Nicola Biagio Mercuri, Marta Camacho, Tommaso Schirinzi
    Movement Disorders Clinical Practice.2025; 12(4): 497.     CrossRef
  • Leveraging animal models to understand non-motor symptoms of Parkinson's disease
    Thomas Wichmann, Alexandra Nelson, Eileen Ruth S. Torres, Per Svenningsson, Roberta Marongiu
    Neurobiology of Disease.2025; 208: 106848.     CrossRef
  • The interrelationship between intestinal immune cells and enteric α-synuclein in the progression of Parkinson’s disease
    Yuan-Kai Cheng, Hao-Sen Chiang
    Neurological Sciences.2025;[Epub]     CrossRef
  • Gastrointestinal Manifestations in Parkinson's Disease Using a Validated Arabic Version of Gastrointestinal Dysfunction Scale: A Multicenter Study
    Ali Soliman Shalash, Marwa Yassien Badr, Yara Salah, Shimaa Elgamal, Shaimaa Ahmed Elaidy, Eman Abdel‐Mageed Elhamrawy, Hayam Abdel‐Tawab, Eman Hamid, Ehab Ahmed El‐Seidy, Noha Lotfy Dawood
    Movement Disorders Clinical Practice.2025;[Epub]     CrossRef
  • Vital nutrition: enhancing health in advanced Parkinson’s disease with device-aided therapies
    Onanong Phokaewvarangkul, Ioanna Markaki, Harmen R. Moes, Igor Petrovic, Anette Schrag, Roongroj Bhidayasiri
    Journal of Neural Transmission.2025;[Epub]     CrossRef
  • Association between cognitive and autonomic dysfunctions in patients with de novo Parkinson’s disease
    Byung-Euk Joo, Jihwan You, Rae On Kim, Kyum-Yil Kwon
    Scientific Reports.2025;[Epub]     CrossRef
  • Associations between gut microbiota characteristics and non‐motor symptoms following pharmacological and surgical treatments in Parkinson's disease patients
    Agnieszka Gorecka‐Mazur, Anna Krygowska‐Wajs, Agata Furgala, Jiaqi Li, Benjamin Misselwitz, Wojciech Pietraszko, Borys Kwinta, Bahtiyar Yilmaz
    Neurogastroenterology & Motility.2024;[Epub]     CrossRef
  • Clinical diagnosis, prevention, and treatment of neurodyspepsia syndrome using intelligent medicine
    Jingyu Zhu, Wei Meng, Liang Liu, Peixin Hu, Yuling Liang, Wenwen Zhu, Xiaoyan Zhu
    Open Life Sciences.2024;[Epub]     CrossRef
  • Levodopa-induced dyskinesia in Parkinson's disease: Insights from cross-cohort prognostic analysis using machine learning
    Rebecca Ting Jiin Loo, Olena Tsurkalenko, Jochen Klucken, Graziella Mangone, Fouad Khoury, Marie Vidailhet, Jean-Christophe Corvol, Rejko Krüger, Enrico Glaab, Geeta Acharya, Gloria Aguayo, Myriam Alexandre, Muhammad Ali, Wim Ammerlann, Giuseppe Arena, Mi
    Parkinsonism & Related Disorders.2024; 126: 107054.     CrossRef
  • Acupuncture for constipation in Parkinson’s disease: A systematic review and meta-analysis of randomized controlled trials
    Zhao Li, Qun Niu, Kai Yang, Keni Zhao, Shao Yin, Fengya Zhu
    Medicine.2024; 103(29): e38937.     CrossRef
  • Alpha Synuclein Toxicity and Non-Motor Parkinson’s
    Gabriella M. Mazzotta, Carmela Conte
    Cells.2024; 13(15): 1265.     CrossRef
  • Novel strategies in Parkinson’s disease treatment: a review
    Charles L. Mitchell, Dmitry Kurouski
    Frontiers in Molecular Neuroscience.2024;[Epub]     CrossRef
  • Advice to People with Parkinson’s in My Clinic: Probiotics and Prebiotics
    Jia Wei Hor, Tzi Shin Toh, Shen-Yang Lim, Ai Huey Tan
    Journal of Parkinson’s Disease.2024; 14(7): 1507.     CrossRef
  • Unmasking bowel obstruction in a Parkinson’s patient: the influence of cognitive bias in frailty medicine
    Harvey Stevenson, Daniele Ramsay, Waseem Jerjes
    Oxford Medical Case Reports.2024;[Epub]     CrossRef
Article image
Multiple System Atrophy: Advances in Diagnosis and Therapy
Hirohisa Watanabe, Sayuri Shima, Yasuaki Mizutani, Akihiro Ueda, Mizuki Ito
J Mov Disord. 2023;16(1):13-21.   Published online December 20, 2022
DOI: https://doi.org/10.14802/jmd.22082
  • 10,014 View
  • 610 Download
  • 10 Web of Science
  • 10 Crossref
AbstractAbstract PDF
This review summarizes improvements in understanding the pathophysiology and early clinical symptoms of multiple system atrophy (MSA) and advancements in diagnostic methods and disease-modifying therapies for the condition. In 2022, the Movement Disorder Society proposed new diagnostic criteria to develop disease-modifying therapies and promote clinical trials of MSA since the second consensus was proposed in 2008. Regarding pathogenesis, cutting-edge findings have accumulated on the interactions of α-synuclein, neuroinflammation, and oligodendroglia with neurons. In neuroimaging, introducing artificial intelligence, machine learning, and deep learning has notably improved diagnostic accuracy and individual analyses. Advancements in treatment have also been achieved, including immunotherapy therapy against α-synuclein and serotonin-targeted and mesenchymal stem cell therapies, which are thought to affect several aspects of the disease, including neuroinflammation. The accelerated progress in clarifying the pathogenesis of MSA over the past few years and the development of diagnostic techniques for detecting early-stage MSA are expected to facilitate the development of disease-modifying therapies for one of the most intractable neurodegenerative diseases.

Citations

Citations to this article as recorded by  
  • Integrative Analysis of Metabolome and Proteome in the Cerebrospinal Fluid of Patients with Multiple System Atrophy
    Nimisha Pradeep George, Minjun Kwon, Yong Eun Jang, Seok Gi Kim, Ji Su Hwang, Sang Seop Lee, Gwang Lee
    Cells.2025; 14(4): 265.     CrossRef
  • Characteristics of cerebral glucose metabolism in patients with cognitive impairment in multiple system atrophy
    Bin Chen, Lingchao Li, Lin Bai, Min Zhao, Ying Chang, Shi Gao
    Frontiers in Aging Neuroscience.2025;[Epub]     CrossRef
  • Comparing a BCI communication system in a patient with Multiple System Atrophy, with an animal model
    Brian Premchand, Kyaw Kyar Toe, Chuanchu Wang, Kai Rui Wan, Thevapriya Selvaratnam, Valerie Ethans Toh, Wai Hoe Ng, Camilo Libedinsky, Weiguo Chen, Ruiqi Lim, Ming-Yuan Cheng, Yuan Gao, Kai Keng Ang, Rosa Qi Yue So
    Brain Research Bulletin.2025; 223: 111289.     CrossRef
  • Trajectories of Pontine Volume in Patients with Multiple System Atrophy
    Kazuya Kawabata, Florian Krismer, Mizuki Ito, Kazuhiro Hara, Epifanio Bagarinao, Vincent Beliveau, Patrice Péran, Germain Arribarat, Anne Pavy‐Le Traon, Wassilios G. Meissner, Alexandra Foubert‐Samier, Margherita Fabbri, Mark Forrest Gordon, Aya Ogura, Ma
    Movement Disorders.2025;[Epub]     CrossRef
  • Multiple System Atrophy (Cerebellar Type) With Overlapping Progressive Muscular Atrophy Features and Genetic Erb-B2 Receptor Tyrosine Kinase 4 (ERBB4) Amyotrophic Lateral Sclerosis Variant: A Case Report
    Enrique Lorenzo C Panganiban, Raymond L Rosales
    Cureus.2025;[Epub]     CrossRef
  • A Blinded Evaluation of Brain Morphometry for Differential Diagnosis of Atypical Parkinsonism
    Kazuya Kawabata, Florian Krismer, Beatrice Heim, Anna Hussl, Christoph Mueller, Christoph Scherfler, Elke R. Gizewski, Klaus Seppi, Werner Poewe
    Movement Disorders Clinical Practice.2024; 11(4): 381.     CrossRef
  • The potential of phosphorylated α‐synuclein as a biomarker for the diagnosis and monitoring of multiple system atrophy
    Toufik Abdul‐Rahman, Ranferi Eduardo Herrera‐Calderón, Arjun Ahluwalia, Andrew Awuah Wireko, Tomas Ferreira, Joecelyn Kirani Tan, Maximillian Wolfson, Shankhaneel Ghosh, Viktoriia Horbas, Vandana Garg, Asma Perveen, Marios Papadakis, Ghulam Md Ashraf, Ath
    CNS Neuroscience & Therapeutics.2024;[Epub]     CrossRef
  • Delivering the diagnosis of multiple system atrophy: a multicenter survey on Japanese neurologists’ perspectives
    Miki Yoshitake, Atsuhiko Sugiyama, Takayoshi Shimohata, Nobuyuki Araki, Masahide Suzuki, Kazumoto Shibuya, Kengo Nagashima, Nobutaka Hattori, Satoshi Kuwabara
    BMC Neurology.2024;[Epub]     CrossRef
  • Clinical comparison of the 2008 and 2022 diagnostic criteria for early multiple system atrophy-cerebellar type
    Seoyeon Kim, Kyung Ah Woo, Jung Hwan Shin, Han-Joon Kim, Beomseok Jeon
    Clinical Autonomic Research.2024; 34(6): 609.     CrossRef
  • Ocular Vestibular-Evoked Myogenic Potential Assists in the Differentiation of Multiple System Atrophy From Parkinson’s Disease
    Keun-Tae Kim, Kyoungwon Baik, Sun-Uk Lee, Euyhyun Park, Chan-Nyoung Lee, Tonghoon Woo, Yukang Kim, Seoui Kwag, Hyunsoh Park, Ji-Soo Kim
    Journal of Movement Disorders.2024; 17(4): 398.     CrossRef
Original Article
The Association between the Triglyceride-Glucose Index and the Incidence Risk of Parkinson’s Disease: A Nationwide Cohort Study
Yoonkyung Chang, Ju-young Park, Ji Young Yun, Tae-Jin Song
J Mov Disord. 2025;18(2):138-148.   Published online February 27, 2025
DOI: https://doi.org/10.14802/jmd.24131
  • 540 View
  • 47 Download
AbstractAbstract PDF
Objective
We aimed to investigate the associations of the triglyceride-glucose index, which measures insulin resistance, and the incidence of Parkinson’s disease.
Methods
Our study used the Health Screening Cohort database of the National Health Insurance Service of South Korea (2002–2019). We included 310,021 participants who had no previous history of Parkinson’s disease and for whom more than 3 triglyceride-glucose index measurements were available. A diagnosis of Parkinson’s disease was determined via the International Classification of Diseases Tenth edition (G20) with a specific reimbursement code for rare intractable diseases and a history of prescriptions for anti-Parkinsonism drugs.
Results
During a median of 9.64 years (interquartile range 8.72–10.53), 4,587 individuals (1.5%) had Parkinson’s disease. Based on a multivariable time-dependent Cox proportional hazards model, a per-unit increase in triglyceride-glucose index score was associated with a significantly increased risk of Parkinson’s disease (hazard ratio [HR]: 1.062; 95% confidence interval [CI] 1.007–1.119). In a sensitivity analysis, the triglyceride-glucose index was associated with the incidence of Parkinson’s disease in a non–diabetes mellitus cohort (HR: 1.093; 95% CI 1.025–1.165), but not in the diabetes mellitus cohort (HR: 0.990; 95% CI 0.902–1.087). In a restricted cubic spline analysis, the association between the triglyceride-glucose index and the incidence risk of Parkinson’s disease showed a nonlinear increasing (J-shaped) trend.
Conclusion
Our study demonstrated that higher triglyceride-glucose index scores were associated with the incidence of Parkinson’s disease in the general population, particularly in a nondiabetic mellitus cohort.
Letter to the editor
A Chinese Child With Dystonia Linked to the EIF2AK2 Missense Variant: A Case Report
Lifang Dai, Changhong Ren, Shenghan Guan, Xiaojuan Tian, Hui Xiong, Changhong Ding
J Mov Disord. 2025;18(2):190-192.   Published online February 20, 2025
DOI: https://doi.org/10.14802/jmd.24215
  • 601 View
  • 52 Download
PDF
Review Articles
Article image
Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson’s Disease
Young Cha, Tae-Yoon Park, Pierre Leblanc, Kwang-Soo Kim
J Mov Disord. 2023;16(1):22-41.   Published online January 12, 2023
DOI: https://doi.org/10.14802/jmd.22141
  • 12,956 View
  • 645 Download
  • 23 Web of Science
  • 22 Crossref
AbstractAbstract PDF
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease, affecting 1%–2% of the population over the age of 65. As the population ages, it is anticipated that the burden on society will significantly escalate. Although symptom reduction by currently available pharmacological and/or surgical treatments improves the quality of life of many PD patients, there are no treatments that can slow down, halt, or reverse disease progression. Because the loss of a specific cell type, midbrain dopamine neurons in the substantia nigra, is the main cause of motor dysfunction in PD, it is considered a promising target for cell replacement therapy. Indeed, numerous preclinical and clinical studies using fetal cell transplantation have provided proof of concept that cell replacement therapy may be a viable therapeutic approach for PD. However, the use of human fetal cells remains fraught with controversy due to fundamental ethical, practical, and clinical limitations. Groundbreaking work on human pluripotent stem cells (hPSCs), including human embryonic stem cells and human induced pluripotent stem cells, coupled with extensive basic research in the stem cell field offers promising potential for hPSC-based cell replacement to become a realistic treatment regimen for PD once several major issues can be successfully addressed. In this review, we will discuss the prospects and challenges of hPSC-based cell therapy for PD.

Citations

Citations to this article as recorded by  
  • Nanotechnology in Parkinson’s Disease: overcoming drug delivery challenges and enhancing therapeutic outcomes
    Irfan Ali, Mohammad Adil, Mohammad Imran, Saba Asif Qureshi, Saima Qureshi, Nazeer Hasan, Farhan Jalees Ahmad
    Drug Delivery and Translational Research.2025;[Epub]     CrossRef
  • Emerging Role of Mesenchymal Stromal Cell and Exosome Therapies in Treating Cognitive Impairment
    Vick Key Tew, Muttiah Barathan, Fazlina Nordin, Jia Xian Law, Min Hwei Ng
    Pharmaceutics.2025; 17(3): 284.     CrossRef
  • Advantages and challenges of using allogeneic vs. autologous sources for neuronal cell replacement in Parkinson’s disease: Insights from non-human primate studies
    Marina E. Emborg, Jeanette M. Metzger, Kevin D’Amour, Julia C. Colwell, Lindsey C. Neumann, Ai Zhang, Howard J. Federoff
    Brain Research Bulletin.2025; 224: 111297.     CrossRef
  • Stem Cell-Based Approaches in Parkinson's Disease Research
    Min Seong Kim, Subeen Yoon, Jiwoo Choi, Yong Jun Kim, Gabsang Lee
    International Journal of Stem Cells.2025; 18(1): 21.     CrossRef
  • Central and Peripheral Immunity Responses in Parkinson’s Disease: An Overview and Update
    Ghaidaa Ebrahim, Hunter Hutchinson, Melanie Gonzalez, Abeer Dagra
    Neuroglia.2025; 6(2): 17.     CrossRef
  • RNA-based controllers for engineering gene and cell therapies
    Kei Takahashi, Kate E Galloway
    Current Opinion in Biotechnology.2024; 85: 103026.     CrossRef
  • Precision Medicine in Parkinson's Disease Using Induced Pluripotent Stem Cells
    Min Seong Kim, Hyesoo Kim, Gabsang Lee
    Advanced Healthcare Materials.2024;[Epub]     CrossRef
  • A recent update on drugs and alternative approaches for parkinsonism
    Sneha Kispotta, Debajyoti Das, Shakti Ketan Prusty
    Neuropeptides.2024; 104: 102415.     CrossRef
  • Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders
    Jessica Cohen, Annette Mathew, Kirk D. Dourvetakis, Estella Sanchez-Guerrero, Rajendra P. Pangeni, Narasimman Gurusamy, Kristina K. Aenlle, Geeta Ravindran, Assma Twahir, Dylan Isler, Sara Rukmini Sosa-Garcia, Axel Llizo, Alison C. Bested, Theoharis C. Th
    Cells.2024; 13(6): 511.     CrossRef
  • Continuous immunosuppression is required for suppressing immune responses to xenografts in non-human primate brains
    Su Feng, Ting Zhang, Zhengxiao He, Wenchang Zhang, Yingying Chen, Chunmei Yue, Naihe Jing
    Cell Regeneration.2024;[Epub]     CrossRef
  • The role of neuroinflammation in neurodegenerative diseases: current understanding and future therapeutic targets
    Alhamdu Adamu, Shuo Li, Fankai Gao, Guofang Xue
    Frontiers in Aging Neuroscience.2024;[Epub]     CrossRef
  • Past, present, and future of cell replacement therapy for parkinson’s disease: a novel emphasis on host immune responses
    Tae-Yoon Park, Jeha Jeon, Young Cha, Kwang-Soo Kim
    Cell Research.2024; 34(7): 479.     CrossRef
  • Dopamine synthesis and transport: current and novel therapeutics for parkinsonisms
    Mary Dayne Sia Tai, Gloria Gamiz-Arco, Aurora Martinez
    Biochemical Society Transactions.2024; 52(3): 1275.     CrossRef
  • Experimental models of Parkinson's disease: Challenges and Opportunities
    Roshan Lal, Aditi singh, Shivam watts, Kanwaljit Chopra
    European Journal of Pharmacology.2024; 980: 176819.     CrossRef
  • The prospective role of mesenchymal stem cells in Parkinson's disease
    Pratima Tambe, Vaishali Undale, Avinash Sanap, Ramesh Bhonde, Nishant Mante
    Parkinsonism & Related Disorders.2024; 127: 107087.     CrossRef
  • Current Landscape of iPSC Haplobanks
    Rubén Escribá, Meral Beksac, Annelise Bennaceur-Griscelli, Joel C. Glover, Satu Koskela, Helen Latsoudis, Sergi Querol, Belén Alvarez-Palomo
    Stem Cell Reviews and Reports.2024; 20(8): 2155.     CrossRef
  • Circuit integration by transplanted human neurons
    Qiang Yuan, Su-Chun Zhang
    Current Opinion in Genetics & Development.2024; 89: 102225.     CrossRef
  • The Abnormal Proliferation of Midbrain Dopamine Cells From Human Pluripotent Stem Cells Is Induced by Exposure to the Tumor Microenvironment
    Jun Xue, Dongyan Wu, Yuting Bao, Yifan Wu, Xin Zhang, Liang Chen
    CNS Neuroscience & Therapeutics.2024;[Epub]     CrossRef
  • Potential for Therapeutic-Loaded Exosomes to Ameliorate the Pathogenic Effects of α-Synuclein in Parkinson’s Disease
    David J. Rademacher
    Biomedicines.2023; 11(4): 1187.     CrossRef
  • Neural Stem Cell Therapies: Promising Treatments for Neurodegenerative Diseases
    Amir Gholamzad, Hadis Sadeghi, Maryam Azizabadi Farahani, Ali Faraji, Mahya Rostami, Sajad Khonche, Shirin Kamrani, Mahsa Khatibi, Omid Moeini, Seyed Armit Hosseini, Mohammadmatin Nourikhani, Mehrdad Gholamzad
    Neurology Letters.2023; 2(2): 55.     CrossRef
  • Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson’s disease?
    Z. Pirtošek, V. Leta, P. Jenner, M. Vérin
    Journal of Neural Transmission.2023; 130(11): 1395.     CrossRef
  • Xeno-free generation of new Yazd human embryonic stem cell lines (Yazd4-7) as a prior stage toward good manufacturing practice of clinical-grade raw materials from discarded embryos: A lab resources report
    Fatemeh Hajizadeh-Tafti, Jalal Golzadeh, Fatemeh Akyash, Somayyeh-Sadat Tahajjodi, Ehsan Farashahi-Yazd, Hassan Heidarian-Meimandi, Behrouz Aflatoonian
    International Journal of Reproductive BioMedicine (IJRM).2023; 21(8): 619.     CrossRef
Article image
GBA1 Variants and Parkinson’s Disease: Paving the Way for Targeted Therapy
Young Eun Huh, Tatiana Usnich, Clemens R. Scherzer, Christine Klein, Sun Ju Chung
J Mov Disord. 2023;16(3):261-278.   Published online June 12, 2023
DOI: https://doi.org/10.14802/jmd.23023
  • 7,804 View
  • 483 Download
  • 11 Web of Science
  • 12 Crossref
AbstractAbstract PDF
Glucosylceramidase beta 1 (GBA1) variants have attracted enormous attention as the most promising and important genetic candidates for precision medicine in Parkinson’s disease (PD). A substantial correlation between GBA1 genotypes and PD phenotypes could inform the prediction of disease progression and promote the development of a preventive intervention for individuals at a higher risk of a worse disease prognosis. Moreover, the GBA1-regulated pathway provides new perspectives on the pathogenesis of PD, such as dysregulated sphingolipid metabolism, impaired protein quality control, and disrupted endoplasmic reticulum-Golgi trafficking. These perspectives have led to the development of novel disease-modifying therapies for PD targeting the GBA1-regulated pathway by repositioning treatment strategies for Gaucher’s disease. This review summarizes the current hypotheses on a mechanistic link between GBA1 variants and PD and possible therapeutic options for modulating GBA1-regulated pathways in PD patients.

Citations

Citations to this article as recorded by  
  • Male sex accelerates cognitive decline in GBA1 Parkinson’s disease
    Silvia Paola Caminiti, Micol Avenali, Alice Galli, Rachele Malito, Giada Cuconato, Caterina Galandra, Rosaria Calabrese, Andrea Pilotto, Alessandro Padovani, Fabio Blandini, Daniela Perani, Cristina Tassorelli, Enza Maria Valente
    npj Parkinson's Disease.2025;[Epub]     CrossRef
  • Classification and Genotype–Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review
    Malco Rossi, Susen Schaake, Tatiana Usnich, Josephine Boehm, Nina Steffen, Nathalie Schell, Clara Krüger, Tuğçe Gül‐Demirkale, Natascha Bahr, Teresa Kleinz, Harutyun Madoev, Björn‐Hergen Laabs, Ziv Gan‐Or, Roy N. Alcalay, Katja Lohmann, Christine Klein
    Movement Disorders.2025; 40(4): 605.     CrossRef
  • Challenges in Gaucher disease: Perspectives from an expert panel
    Gregory A. Grabowski, Priya S. Kishnani, Roy N. Alcalay, S. Grace Prakalapakorn, Barry E. Rosenbloom, Dominick A. Tuason, Neal J. Weinreb
    Molecular Genetics and Metabolism.2025; 145(1): 109074.     CrossRef
  • Acetal functionalized iminosugars for targeting β-glucocerebrosidase modulation
    Maria Giulia Davighi, Francesca Clemente, Camilla Matassini, Martina Cacciarini, Damiano Tanini, Andrea Goti, Amelia Morrone, Paolo Paoli, Francesca Cardona
    European Journal of Medicinal Chemistry.2025; 290: 117529.     CrossRef
  • Comparative analysis of methods for measuring glucocerebrosidase enzyme activity in patients with Parkinson’s disease with the GBA1 variant
    Jin Hwangbo, Myung Jun Lee, Sang Jin Kim, Hyun Kyung Park, Jae-heyok Lee
    Frontiers in Neurology.2025;[Epub]     CrossRef
  • A drug screening platform for protein expression levels in neurological disorders
    Farida Emran, Ibrahim Kays, Chiu-An Lo, Yueyang Li, Brian E. Chen
    BioTechniques.2025; : 1.     CrossRef
  • Investigating plasma lipid profiles in association with Parkinson’s disease risk
    Houwen Zhang, Fangzheng Cao, Jialin Yu, Yu Liang, You Wu
    npj Parkinson's Disease.2025;[Epub]     CrossRef
  • A Comparative Biochemical and Pathological Evaluation of Brain Samples from Knock-In Murine Models of Gaucher Disease
    Makaila L. Furderer, Bahafta Berhe, Tiffany C. Chen, Stephen Wincovitch, Xuntian Jiang, Nahid Tayebi, Ellen Sidransky, Tae-Un Han
    International Journal of Molecular Sciences.2024; 25(3): 1827.     CrossRef
  • Towards a Global View of Parkinson's Disease Genetics
    Marzieh Khani, Catalina Cerquera‐Cleves, Mariam Kekenadze, Peter Wild Crea, Andrew B. Singleton, Sara Bandres‐Ciga
    Annals of Neurology.2024; 95(5): 831.     CrossRef
  • Exploring the Association between Cathepsin B and Parkinson’s Disease
    Changhao Lu, Xinyi Cai, Shilin Zhi, Xiaofen Wen, Jiaxin Shen, Tommaso Ercoli, Elena Rita Simula, Carla Masala, Leonardo A. Sechi, Paolo Solla
    Brain Sciences.2024; 14(5): 482.     CrossRef
  • Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson’s disease
    Xuxiang Zhang, Heng Wu, Beisha Tang, Jifeng Guo
    Translational Neurodegeneration.2024;[Epub]     CrossRef
  • Microglia: roles and genetic risk in Parkinson’s disease
    Alex R. Trainor, Debra S. MacDonald, Jay Penney
    Frontiers in Neuroscience.2024;[Epub]     CrossRef
Article image
Evidence-Based Review on Symptomatic Management of Huntington’s Disease
Jung Hwan Shin, Hui-Jun Yang, Jong Hyun Ahn, Sungyang Jo, Seok Jong Chung, Jee-Young Lee, Hyun Sook Kim, Manho Kim
J Mov Disord. 2024;17(4):369-386.   Published online August 9, 2024
DOI: https://doi.org/10.14802/jmd.24140
Correction in: J Mov Disord 2025;18(1):111
  • 3,792 View
  • 223 Download
  • 2 Web of Science
  • 1 Crossref
  • 2 Comments
AbstractAbstract PDFSupplementary Material
Huntington’s disease (HD) is a neurodegenerative disorder characterized by motor, behavioral, and cognitive impairments and significant impacts on patient quality of life. This evidence-based review, conducted by the Korean Huntington Disease Society task force, systematically examines current pharmacological and nonpharmacological interventions for symptomatic management of HD. Following PRISMA guidelines, databases were searched for studies up to August 2022 that focused on 23 symptoms across four domains: motor, neuropsychological, cognition, and others. This review provides a comprehensive and systematic approach to the management of HD, highlighting the need for more high-quality clinical trials to develop robust evidence-based guidelines.

Citations

Citations to this article as recorded by  
  • A Practical Guide for Diagnostic Investigations and Special Considerations in Patients With Huntington’s Disease in Korea
    Jangsup Moon, Eungseok Oh, Minkyeong Kim, Ryul Kim, Dallah Yoo, Chaewon Shin, Jee-Young Lee, Jong-Min Kim, Seong-Beom Koh, Manho Kim, Beomseok Jeon
    Journal of Movement Disorders.2025; 18(1): 17.     CrossRef
Original Articles
Article image
Efficacy and Safety of Taltirelin Hydrate in Patients With Ataxia Due to Spinocerebellar Degeneration
Jin Whan Cho, Jee-Young Lee, Han-Joon Kim, Joong-Seok Kim, Kun-Woo Park, Seong-Min Choi, Chul Hyoung Lyoo, Seong-Beom Koh
J Mov Disord. 2025;18(1):35-44.   Published online October 21, 2024
DOI: https://doi.org/10.14802/jmd.24127
  • 1,923 View
  • 230 Download
  • 1 Comments
AbstractAbstract PDFSupplementary Material
Objective
We conducted this study to assess the efficacy and safety of taltirelin hydrate (TH) in patients with ataxia due to spinocerebellar degeneration (SCD).
Methods
Patients were randomly assigned to either the taltirelin group (5 mg orally, twice daily) or the control group. The primary endpoint was the change in the Korean version of the Scale for the Assessment and Rating of Ataxia (K-SARA) score at 24 weeks. The secondary endpoints included changes in the K-SARA score at 4 and 12 weeks as well as the Clinical Global Impression Scale, the five-level version of the EuroQol five-dimensional questionnaire, the Tinetti balance test, and gait analysis at 4, 12, and 24 weeks.
Results
A total of 149 patients (hereditary:nonhereditary=86:63) were enrolled. There were significant differences in the change in the K-SARA score at 24 weeks from baseline between the taltirelin group and the control group (-0.51±2.79 versus 0.36±2.62, respectively; p=0.0321). For the K-SARA items, the taltirelin group had significantly lower “Stance” and “Speech disturbance” subscores than the control group (-0.04±0.89 versus 0.23±0.79 and -0.07±0.74 versus 0.18±0.67; p=0.0270 and 0.0130, respectively). However, there were no significant differences in changes in other secondary efficacy outcome measures at 24 weeks from baseline between the two treatment arms (p>0.05).
Conclusion
Clinicians might consider the use of TH in the treatment of patients with ataxia due to SCD.
Feasibility of a Multidomain Intervention for Safe Mobility in People With Parkinson’s Disease and Recurrent Falls
Natalie E Allen, Lina Goh, Colleen G Canning, Catherine Sherrington, Lindy Clemson, Jacqueline CT Close, Stephen R Lord, Simon J G Lewis, Simone Edwards, Susan Harkness, Roslyn Savage, Lyndell Webster, Genevieve Zelma, Serene S Paul
J Mov Disord. 2025;18(2):149-159.   Published online March 14, 2025
DOI: https://doi.org/10.14802/jmd.24237
  • 494 View
  • 33 Download
AbstractAbstract PDF
Objective
Mobility limitations and falls are common in people with Parkinson’s disease (PwP). Compared with exercise alone, a tailored, multidomain intervention has the potential to be more effective in improving mobility safety and preventing falls. This study aimed to explore the feasibility and potential effectiveness of a multidomain fall prevention intervention (Integrate) designed for PwP who experience frequent falls.
Methods
The home-based intervention was delivered over a span of 6 months by occupational therapists and physiotherapists. The personalized intervention included home fall hazard reduction, exercise, and safer mobility behavior training. The participants received 8 to 12 home visits and were supported by care-partners (when necessary) to participate in the intervention.
Results
Twenty-nine people (recruitment rate: 49%; drop-out rate: 10%) with moderate to advanced Parkinson’s disease, a history of recurrent falls, and mild to moderate cognitive impairment participated in the study, with 26 people completing the study. A moderate-to-high adherence to the intervention was observed, and there were no adverse events related to the intervention. Twenty-one (81%) participants met or exceeded their safer mobility goal based on the Goal Attainment Scale. The participants exhibited a median 1.0-point clinically meaningful improvement according to the Short Physical Performance Battery. An exploratory analysis revealed that fall rates were reduced by almost 50% in the 6-month follow-up period (incidence rate ratio: 0.51; 95% confidence interval 0.28–0.92).
Conclusion
A multidomain occupational therapy and physiotherapy intervention for PwP experiencing recurrent falls was feasible and appeared to improve mobility safety. A randomized trial powered to detect the effects of the intervention on falls and mobility is warranted.

JMD : Journal of Movement Disorders Twitter
Close layer
TOP